168 related articles for article (PubMed ID: 38073374)
1. Circulating miR-10b, soluble urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 as predictors of non-small cell lung cancer progression and treatment response.
Setiawan L; Setiabudy R; Kresno SB; Sutandyo N; Syahruddin E; Jovianti F; Nadliroh S; Mubarika S; Setiabudy R; Siregar NC
Cancer Biomark; 2024; 39(2):137-153. PubMed ID: 38073374
[TBL] [Abstract][Full Text] [Related]
2. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
3. The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer.
Wach S; Al-Janabi O; Weigelt K; Fischer K; Greither T; Marcou M; Theil G; Nolte E; Holzhausen HJ; Stöhr R; Huppert V; Hartmann A; Fornara P; Wullich B; Taubert H
Int J Cancer; 2015 Sep; 137(6):1406-16. PubMed ID: 25754273
[TBL] [Abstract][Full Text] [Related]
4. Thrombo-inflammatory biomarkers to predict sepsis outcome.
Efat A; Shoeib SA; Arafa AF; Dawod AA; Abd ElHafez MA; Abd ElMohsen EA; Eladly HF; Ibrahim RA; Elkholy A
Int J Immunopathol Pharmacol; 2021; 35():20587384211048561. PubMed ID: 34647483
[TBL] [Abstract][Full Text] [Related]
5. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis.
Di Bernardo MC; Matakidou A; Eisen T; Houlston RS;
Lung Cancer; 2009 Aug; 65(2):237-41. PubMed ID: 19117638
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy.
Schuettfort VM; Pradere B; D'Andrea D; Grossmann NC; Quhal F; Mostafaei H; Laukhtina E; Mori K; Rink M; Karakiewicz PI; Motlagh RS; Katayama S; Lotan Y; Scherr D; Abufaraj M; Fajkovica H; Compérat E; Enikeev D; Shariat SF
J Urol; 2021 Nov; 206(5):1122-1131. PubMed ID: 34181469
[TBL] [Abstract][Full Text] [Related]
8. Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease.
Wang H; Yang T; Li D; Wu Y; Zhang X; Pang C; Zhang J; Ying B; Wang T; Wen F
Int J Chron Obstruct Pulmon Dis; 2016; 11():2369-2376. PubMed ID: 27713627
[TBL] [Abstract][Full Text] [Related]
9. Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.
Yeh YH; Wang PH; Lin LY; Tee YT; Chou MC; Yang SF; Tsai HT
Clin Chim Acta; 2013 Jan; 415():138-44. PubMed ID: 23117033
[TBL] [Abstract][Full Text] [Related]
10. Assessment of clinical utility and predictive potential of pre-chemotherapy soluble urokinase plasminogen activator receptor: Observational single center study.
Beleva E; Stoencheva S; Deneva T; Nenova I; Grudeva-Popova Z
Biomol Biomed; 2023 Mar; 23(2):287-297. PubMed ID: 36124441
[TBL] [Abstract][Full Text] [Related]
11. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
[TBL] [Abstract][Full Text] [Related]
12. Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
Pappot H; Skov BG; Pyke C; Grøndahl-Hansen J
Lung Cancer; 1997 Jul; 17(2-3):197-209. PubMed ID: 9237155
[TBL] [Abstract][Full Text] [Related]
13. SuPAR and PAI-1 in critically ill, mechanically ventilated patients.
Jalkanen V; Yang R; Linko R; Huhtala H; Okkonen M; Varpula T; Pettilä V; Tenhunen J;
Intensive Care Med; 2013 Mar; 39(3):489-96. PubMed ID: 23100007
[TBL] [Abstract][Full Text] [Related]
14. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
Offersen BV; Pfeiffer P; Andreasen P; Overgaard J
Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
[TBL] [Abstract][Full Text] [Related]
16. The urokinase-type plasminogen activator and inhibitors in resectable lung adenocarcinoma.
Zhu C; Jiang L; Xu J; Ren A; Ju F; Shu Y
Pathol Res Pract; 2020 Apr; 216(4):152885. PubMed ID: 32113794
[TBL] [Abstract][Full Text] [Related]
17. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
[TBL] [Abstract][Full Text] [Related]
18. Longitudinally Measured Fibrinolysis Factors are Strong Predictors of Clinical Outcome in Patients with Chronic Heart Failure: The Bio-SHiFT Study.
van den Berg VJ; Bouwens E; Umans VAWM; de Maat M; Manintveld OC; Caliskan K; Constantinescu AA; Mouthaan H; Cornel JH; Baart S; Akkerhuis KM; Boersma E; Kardys I
Thromb Haemost; 2019 Dec; 119(12):1947-1955. PubMed ID: 31659734
[TBL] [Abstract][Full Text] [Related]
19. The Plasma Soluble Urokinase Plasminogen Activator Receptor Is Related to Disease Activity of Patients with ANCA-Associated Vasculitis.
Huang F; Li Y; Xu R; Cheng A; Lv Y; Liu Q
Mediators Inflamm; 2020; 2020():7850179. PubMed ID: 32322165
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment determination of the serum urokinase plasminogen activator and its soluble receptor in advanced small-cell lung cancer or non-small-cell lung cancer.
Cobos E; Jumper C; Lox C
Clin Appl Thromb Hemost; 2003 Jul; 9(3):241-6. PubMed ID: 14507113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]